CME Lesson

Safety of Baricitinib 4 mg for the Treatment of Rheumatoid Arthritis

Click the Play button above to access the podcast.

Subscribe: AppleGoogleSpotifyYouTubeiHeartRadioStitcher Radio

References & Resources

  1. Dabal TD, Halton MB, Patel PP, et al. Safety of baricitinib for 4 mg for the treatment of moderate to severe rheumatoid arthritis. South Med J 2021;114:288-292.
  2. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68:1–25.
  3. Keystone EC, Genovese MC, Schlichting DE, et al. Safety and efficacy of baricitinib through 128 weeks in an open-label, long-term extension study in patients with rheumatoid arthritis. J Rheumatol 2018;45:14–21.
  4. Eli Lilly and Company. FDA Briefing Document. Arthritis Advisory Committee Meeting, April 23, 2018. NDA 207924, Baricitinib Janus Kinase (JAK) inhibitor for RA. Published 2018. Accessed February 28, 2021.Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 2019;58:1755–1766.

After reviewing the content and resources, click below to take the course quizzes.